We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

2 hedge funds and large institutions have $677K invested in ProShares UltraShort NASDAQ Biotechnology in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

17.89% more ownership

Funds ownership: 12.2% → 30.1% (+18%)

12% more capital invested

Capital invested by funds: $606K → $677K (+$71.4K)

50% less funds holding

Funds holding: 4 → 2 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$191K
2
TRCT
Tower Research Capital (TRC)
New York
+$69.5K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$21
2
UBS Group
UBS Group
Switzerland
-$9

BIS Hedge Fund Activity: Q2 2026 in Review

2 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2026, worth a combined $677K — up 12% from $606K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BIS and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna International Group, adding an estimated $191K. The largest seller was Morgan Stanley, exiting entirely with an estimated $21 sold.

  • 2 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2026, down from 4 in Q1 2026.
  • Funds reported $677K of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2026, up 12% quarter-over-quarter.
  • 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2026 and 2 closed out, a net change of -2 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2026 was Susquehanna International Group, an estimated $191K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2026 was Morgan Stanley, an estimated $21 sold.

Based on aggregated 13F filings for Q2 2026.